Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of wnt inhibitor wnt-c59 in preparation of medicine for scn5a mutation-induced dilated cardiomyopathy

A technology of dilated cardiomyopathy and wnt-c59, which is applied in the field of biomedicine to achieve good application prospects and improve the effect of cardiac function prognosis

Active Publication Date: 2021-08-31
ZHONGSHAN HOSPITAL FUDAN UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is no report about the application of the Wnt inhibitor Wnt-C59 of the present invention in the preparation of drugs for the treatment of dilated cardiomyopathy caused by SCN5A mutations

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of wnt inhibitor wnt-c59 in preparation of medicine for scn5a mutation-induced dilated cardiomyopathy
  • Application of wnt inhibitor wnt-c59 in preparation of medicine for scn5a mutation-induced dilated cardiomyopathy
  • Application of wnt inhibitor wnt-c59 in preparation of medicine for scn5a mutation-induced dilated cardiomyopathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Embodiment 1 Animal experiment

[0026] 1 method

[0027] 1.1 Preparation of experimental animals and animal models

[0028] SPF grade male C57BL / 6 mice (purchased from Shanghai Jiesijie Experimental Animal Co., Ltd.) and SCN5A heterozygous mutant mice were selected, aged 8-10 weeks, weighing 20-25g, and treated with d-galactose (500mg / kg.d, sigma G5388) were injected intraperitoneally for 8 weeks to construct an aging model. Then, doxorubicin (10 mg / kg in total, injected intraperitoneally in 4 times, Sanko A603456) was used to construct a heart expansion model. After the model was established, the cardiomyocytes of mice in the KI group and the WT group were isolated. The experimental protocol was approved by the Animal Management and Ethics Committee of Fudan University.

[0029] Animal experiments have shown that there is no statistical difference in heart function between SCN5A heterozygous mutant mice and wild-type mice in the natural aging model, the simple ga...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of biomedicine, in particular to the application of Wnt inhibitor Wnt-C59 in the preparation of medicines for treating dilated cardiomyopathy caused by SCN5A mutation. The present invention proposes for the first time that SCN5A genotype detection is used as an entry point, and the Wnt pathway-specific inhibitor Wnt-C59 is used to inhibit the abnormal activation of the Wnt / β-Catenin pathway caused by the SCN5A gene mutation, so as to improve the dilated cardiomyopathy caused by the SCN5A gene mutation Patient cardiac function prognosis. The experiment established a model of heart dilation induced by aging combined with doxorubicin, and detected the therapeutic effect of Wnt‑C59 on heart dilation by changes in cardiac function and activation of related signaling molecules, so as to provide a theory for the clinical application of Wnt‑C59 in the treatment of dilated cardiomyopathy in accordance with. The invention provides a new treatment method for SCN5A mutation-induced dilated cardiomyopathy, brings dawn to this type of patients, and has a good application prospect.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the application of Wnt inhibitor Wnt-C59 in the preparation of drugs for treating dilated cardiomyopathy caused by SCN5A mutation. Background technique [0002] Primary dilated cardiomyopathy (dilated heart disease) refers to the irreversible decline in heart function caused by heart enlargement. The prevalence of the population is about 40 / 100,000, and the 5-year mortality rate reaches 50%. There is no specific treatment plan. Cardiac expansion caused by genetic factors accounts for about 20-30%. It was initially found that the pathogenic genes mostly encode cell structural proteins, such as cardiac actin (actin) gene, nuclear lamin (laminA / C) gene, etc., due to damage Cellular stress transmission leads to myocardial damage and heart enlargement. In 2004, McNair proposed for the first time that the mutation of the cardiac sodium channel gene (SCN5A) was related to heart exp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/444A61P9/04
CPCA61K31/444A61P9/04Y02A50/30
Inventor 葛均波孙爱军胡静静杨坤
Owner ZHONGSHAN HOSPITAL FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com